GlassScriptPhysician profile
Suad A Ismail
NPI 1578546792
$49,477.56
in general payments reported to CMS, 2019-2025
19 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $14K · 2021: $4,410 · 2022: $4,141 · 2023: $1,297 · 2024: $1,142 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,768.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $26,863.83 | 2019-2023 | |
| Amgen INC. | $16,921.65 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $2,207.98 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $846.03 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $583.84 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $552.75 | 2020-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $348.12 | 2019-2025 | Eliquis, Camzyos |
| Cvrx, INC. | $321.27 | 2022-2024 | Barostim Neo System |
| Esperion Therapeutics, INC. | $170.16 | 2020-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $162.83 | 2019-2023 | |
| Biotronik INC. | $130.27 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $106.18 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $74.88 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $69.08 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.34 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $22.97 | 2023 | Rybelsus, Ozempic |
| Aegerion Pharmaceuticals, INC. | $21.65 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.03 | 2019 | |
| Azurity Pharmaceuticals, INC. | $18.70 | 2025 | Nymalize |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suad Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.